elaprase
takeda israel ltd - idursulfase - concentrate for solution for infusion - idursulfase 2 mg/ml - idursulfase - idursulfase - long term treatment of patients with hunter syndrome (mps ii).
elaprase
takeda pharmaceuticals international ag ireland branch - idursulfase - mucopolysaccharidosis ii - other alimentary tract and metabolism products, - elaprase is indicated for the long-term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii). heterozygous females were not studied in the clinical trials.
elaprase (tm) solution for intravenous infusion 2mg ml
sanofi-aventis singapore pte. ltd. - idursulfase - infusion, solution concentrate - 6.0 mg/vial - idursulfase 6.0 mg/vial
elaprase solution
takeda canada inc - idursulfase - solution - 2mg - idursulfase 2mg - enzymes
elaprase 2 mg/ml concentrate for solution for infusion
shire human genetic therapies ab, sweden - idursulfase - concentrate for solution for infusion - 2 mg/ml
elaprase 2 mg/ml concentrate for solution for infusion
shire human genetic therapies ab, sweden - idursulfase - concentrate for solution for infusion - 2 mg/ml
elaprase
pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml; - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).
elaprase 6mg3ml concentrate for solution for infusion vials
shire pharmaceuticals ltd - idursulfase - solution for infusion - 2mg/1ml